NEW YORK (GenomeWeb News) – UK amplification firm Sirigen today announced it has raised about £3.8 million ($6.1 million) in two completed rounds of financing, which it will use to support commercialization of its High Sensitivity Fluorescence technology.
Leading the rounds was a syndicate of new investors including IQ Capital, the National Endowment for Science, Technology, and the Arts, and YFM Private Equity. Existing investors Seraphim Capital and Oxford Capital Partners also participated.
According to Sirigen's website, its HSF technology overcomes fluorescent detection's dependence on the performance of reporter dyes that are used and their ability to absorb excitation light. The HSF polymers are designed "for maximal absorption of exciting light and conversion to fluorescent signal."
The firm said that its technology can be used in a wide range of assay formats and applications including multiplex and molecular diagnostics, microarrays, and DNA sequencing.
The company also announced that Ivan Griffin at NESTA and Max Bautin at IQ Capital have been appointed investor directors at Sirigen. David Evans was appointed chairman of the board and Arthur Cole was appointed as a non-executive director.
Evans is the former CFO of Shield Diagnostics and is chairman and non-executive director at a number of diagnostic and life science companies. He also was chairman of DxS, a molecular diagnostic firm acquired by Qiagen last year.
Cole was executive vice president of Visible Genetics and vice president of new business development at Pharmacia Biotech.